Skip to main content UVA Health School of Medicine Logo UVA Health School of Medicine Logo
The Making of Medicine

Good News in the Battle Against the Most Common Childhood Cancer

Stem cell transplants can dramatically reduce the relapse rate in children who receive CAR T-cell therapy for acute lymphoblastic leukemia, a new study from our Daniel "Trey" Lee, MD, finds.

CAR T-cell therapy weaponizes the body's immune cells to become better cancer killers. It results in complete remission in 60%-100% of the young patients initially, but the relapse rate is high -- one study found that more than 40% had relapsed 13.1 months later.

But stem cell transplants make a big difference, according to Dr. Lee's new study. Among 21 young people who received an allogenic stem cell transplant after CARs, only 9.5% had relapsed 24 months later. In comparison, all of those who did not receive a stem-cell transplant had relapsed.

The study looked at a total of 50 patients ages 4 to 30, with a median age of 13.5 years.

“Even as impactful as CAR T-cell therapy is for children with relapsed leukemia, we now know that the best outcomes happen when the child undergoes a stem cell transplant afterwards,” said Dr. Lee, of UVA Cancer Center. “Many parents turn to CAR T-cells to possibly avoid a stem cell transplant, and that is entirely understandable. But there is a window of opportunity after CARs to cure more of these incurable kids with a transplant; our study demonstrates this.”

For his next steps, Dr. Lee hopes to develop a way to identify which children need a stem-cell transplants and which do not.

Reply & View Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe